Associated Papers
Pharmacogenomics of CYP3A: considerations for HIV treatment.
Lakhman SS et al.
Pharmacogenomics, 2009
Polymorphisms of drug-metabolizing enzymes (GST, CYP2B6 and CYP3A) affect the pharmacokinetics of thiotepa and tepa.
Ekhart C et al.
British Journal of Clinical Pharmacology, 2009
CYP450 pharmacogenetics for personalizing cancer therapy.
van Schaik RH
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy, 2008
Recombinant CYP3A4*17 is defective in metabolizing the hypertensive drug nifedipine, and the CYP3A4*17 allele may occur on the same chromosome as CYP3A5*3, representing a new putative defective CYP3A haplotype.
Lee SJ et al.
The Journal of Pharmacology and Experimental Therapeutics, 2005
An interethnic comparison of polymorphisms of the genes encoding drug-metabolizing enzymes and drug transporters: experience in Singapore.
Chowbay B et al.
Drug Metabolism Reviews, 2005
Identification and functional characterization of eight CYP3A4 protein variants.
Eiselt R et al.
Pharmacogenetics, 2001
Sequence diversity and haplotype structure at the human CYP3A cluster.
Thompson EE et al.
The Pharmacogenomics Journal, 0
Select a paper to view details